(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes.

Slides:

Advertisements

Similar presentations

Anti-nuclear antibodies

Advertisements

ANTI-Ro/SSA 52 ANTIBODIES IN AUTOIMMUNE DISEASES Coordinator: Monica Copotoiu MD,PhD First author: Gabriela Mihai Coauthors: Isabela Micu, Mihaela Budianu,

3. AUTOIMMUNITY Immune Mechanisms Tolerance 4. Rheumatologic diseases

Copyright © 2004 American Medical Association. All rights reserved.

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Figure 2 Shared genetic loci in systemic autoimmune diseases

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Percentage of patients achieving minimal disease activity (MDA): A

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 1 IFA testing for identifying the presence of ANAs

Figure 2 Overlap of associated loci among five rheumatic diseases

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 3 Multi-hit model for autoimmune diseases

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Nat. Rev. Rheumatol. doi: /nrrheum

Updated 2016 PsA Core Domain Set.

Nat. Rev. Rheumatol. doi: /nrrheum

Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Immunoadsorption of anti-Rpp25 antibodies.

Clinical and serological evolution of the presented case.

Jack C. O’Brien, Benjamin F. Chong

Elbow pain: a guide to assessment and management in primary care

A clinical overview of autoantibodies in general practice rheumatology

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Nat. Rev. Nephrol. doi: /nrneph

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Association of pretreatment interferon (IFN) signature metric (ISM) status with serum autoantibodies, BAFF levels and type I IFN bioactivity. Association.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

C.2.10 Sample Questions.

Suggested diagnostic protocol for investigation of suspected SLE

Jack C. O’Brien, Benjamin F. Chong

Association of B cell TLR4 levels to disease activity.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient disposition, weeks 24–128.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

Pulmonary vaccination induces a long-term immune memory response to antigen challenge. Pulmonary vaccination induces a long-term immune memory response.

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc) cause immune-mediated.

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Antinuclear antibody (ANA) patterns (using HEp-2 ANA assay kit) and anti-dsDNA (analysed by Crithidia luciliae assay) in sera of the lpr-water, lpr-CU.

Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Two-tier.

Antibody levels to Ro52, Ro60, p200 and La antigens in control and congenital heart block (CHB) cohort were measured as bound units (BU). Antibody levels.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Frequency of misrepair studies with increasing concentrations of antibodies against NHEJ repair proteins. Frequency of misrepair studies with increasing.

Ligation efficiency is abrogated with increasing concentration of antibodies against NHEJ proteins. Ligation efficiency is abrogated with increasing concentration.

Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.

Fluorescein angiogram of the right eye shows patchy staining of the peripheral retinal veins in the right eye, and nonperfusion of the peripheral retina.

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

Microscopic findings from the skin biopsy.

Fig. 4: Schematic, initial diagnostic algorithm for a patient presenting with mild aminotransferase abnormality. Fig. 4: Schematic, initial diagnostic.

Presentation transcript:

(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (B) Proposed new ANA test algorithm considering anti-DFS70 antibodies on all ANA-positive samples. ANA: antinuclear antibodies; DFS: dense fine speckled; ENA: extractable nuclear antigen; SARD: systemic autoimmune rheumatic diseases. STACEY LUCAS et al. J Rheumatol 2018;45:289-291 ©2018 by The Journal of Rheumatology